Multiple mechanisms of resistance to CDK4/6 inhibitors activate the MAPK pathway in HR + metastatic breast cancer cells [65], thus the sensitivity of our model to MEK inhibition may be extended to additional agents that target the MAPK pathway. This evidence concerns the gene CDK4 and breast carcinoma.